Central Serous Chorioretinopathy: Signal to Reduce Corticoid in Renal Transplant Recipients?

• DOI: 10.1016/j.transproceed.2015.07.017
• Publication Date: 2015-09-08T22:02:30Z
• Authors: P.-B. Ou-yang; X. Qi; X.-H. Zhu; X.-C. Duan
• Keywords: Male; 0301 basic medicine; Visual Acuity; Retinal Pigment Epithelium; Middle Aged; Kidney Transplantation; Transplant Recipients; 3. Good health; 03 medical and health sciences; Glomerulonephritis; Postoperative Complications; Treatment Outcome; 0302 clinical medicine; Central Serous Chorioretinopathy; Adrenal Cortex Hormones; Humans; Tomography, Optical Coherence; Retrospective Studies

The aim of this work was to report the treatment effectiveness of central serous chorioretinopathy (CSCR) in a renal transplant recipient who received conventional therapy with little effect, and then reducing corticoid successively and with a better outcome later.We performed a retrospective comparison of best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) of a 57-year-old renal transplant recipient who received conventional therapy and reducing corticoid successively after he was diagnosed as CSCR in the left eye.The BCVA of the left eye stayed at 20/200 after 3 months' conventional therapy, but rapidly improved to 20/25 after reducing corticoid by one-half. At the same time, SD-OCT showed much more obvious absorption of retinal liquid in the left eye from reducing corticoid than from conventional therapy. Despite the reducing of corticoid by one-half, the patient did not show any signs of rejection of the renal transplant.CSCR may be a sign in renal transplant recipients for reducing corticoid, and reducing corticoid might be a more reliable and safer treatment for such patients.